June 29, 2010 - Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular diseases, announces positive safety data and preliminary efficacy results from its clinical trial of C‐Cure®, a breakthrough stem cell therapy for heart failure.Results showed C‐Cure to have a very good safety profile with no adverse events related to C‐Cure, as assessed by an independent board. The study is also examining a number of measures of efficacy. With three month follow up data in‐hand, Cardio3 BioSciences has observed positive and encouraging trends in a number of physiological and clinical parameters. Meaningful differences were seen in ventricular size, ejection fraction and other measures of heart muscle activity in C‐Cure treated patients when compared to control and to baseline. Partial data from a paired analysis of patients at six‐months follow‐up is suggestive of these beneficial trends being reinforced over time. Cardio3 Biosciences intends to publish the study results once the full six month dataset is available and has been analysed... [PDF] Cardio3 BioSciences' Press Release -
